High-Dose Regimen of nusinersen receives European Commission Approval for the treatment of SMA
High-Dose Regimen of nusinersen receives European Commission Approval for the treatment of SMA.
Biogen announced that the European Commission has granted marketing authorisation for a high-dose regimen of nusinersen (SPINRAZA®) for the treatment of SMA. The high-dose regimen comprises a more rapid loading phase, with two 50 mg loading doses administered 14 days apart, and 28 mg maintenance dose injections every four months thereafter.